Headlines,Eli Lilly Shares Experience a Decline,Key Analyst Activity and Ratings for LLY,What's Next for Eli Lilly's ...

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million ...

Next up, Tremfya made a triumphant return to the 2024 roundup after falling off the rankings in 2023. The med's return came ...

Like Bio-Hermes-001, the Bio-Hermes-002 study is setting a standard for improving participation from people who are traditionally underrepresented in Alzheimer's clinical research, with an ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Eli Lilly has been unable to secure an accelerated ... study and comparisons inevitably drawn between it and the CLARITY-AD study of Leqembi, which revealed a 27% reduction in cognitive decline ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...